# SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer

> **NCT06990503** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06990503
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2030-06-01
- **Final completion:** 2035-06-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06990503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06990503, "SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06990503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*